Aug 2026· International Journal of Radiation Oncology, Biology, Physics· 0 citations
Medicine
TL;DR
An untargeted proteomics profiling comparing pMBRT with conventional proton therapy in an orthotopic rat model of GB highlighted the dual capacity of pMBRT to sensitise tumours to radiation while preserving healthy brain tissue, supporting its translational potential for GB treatment.
Abstract
Purpose
Glioblastoma (GB) is an aggressive primary brain tumour with limited therapeutic options. Although radiotherapy (RT) remains a cornerstone of treatment, its efficacy is constrained by collateral damage to healthy brain tissue. Proton minibeam radiotherapy (pMBRT), a spatially fractionated modality, has shown promise in preclinical models and early clinical applications by mitigating normal tissue toxicity while enhancing tumour control. Notably, previous studies in rats have reported long-term neuroprotective effects following brain irradiation, as well as the emergence of long-term survivors accompanied by immune memory in GB-bearing models. To investigate the underlying radiobiological mechanisms of pMBRT, we performed an untargeted proteomics profiling comparing pMBRT with conventional proton therapy (CPT) in an orthotopic rat model of GB.
Methods
AND MATERIALS
Male Fischer rats were orthotopically injected with 50,000 RG2 cells into the right caudate nucleus. After validation of tumour uptake at day 13 by bioluminescence, rats received pMBRT or CPT treatment at day 14. Seven days after irradiation, brains were harvested to perform proteomics analysis and immunofluorescence staining.
Results
Both modalities attenuated proliferative signalling in tumours after seven days; however, pMBRT was associated with distinct metabolic modulation in tumours, notably upregulation of vanin-1 and attenuated glutamine synthetase induction, changes that may reflect increased tumour radiosensitivity. These alterations were further validated via immunofluorescence on brain cryosections. In normal brain, pMBRT was associated with preservation of synaptic-related protein expression and modulation of nitrogen metabolism, including altered glutamate dehydrogenase levels.
Conclusions
Collectively, these findings highlight the dual capacity of pMBRT to sensitise tumours to radiation while preserving healthy brain tissue, supporting its translational potential for GB treatment.
Medulloblastoma is the most common malignant childhood brain tumour. Radiotherapy (RT) forms a key treatment pillar but is associated with significant late effects. Ex vivo brain slice cultures present a translational model that overcomes limitations of existing in vitro and in vivo alternatives. Slice cultures p...
Kristy Kehoe, Louisa Taylor, M. Beckett et al.· Neuro-Oncology· 0 citations
BACKGROUND
Spatially fractionated radiotherapy (SFRT) is an emerging therapeutic strategy that enhances tumor control while reducing normal tissue toxicity. Although conventional radiotherapy is known to induce therapy-induced senescence (TIS), its induction by SFRT-particularly mini-GRID radiotherapy-remains poorly ch...
M. Acuña, M. Prados, S. Da Silva-Álvarez et al.· Aging· 0 citations
PURPOSE OF REVIEW
Glioblastoma is the most aggressive and treatment-resistant primary brain tumor in adults. Given its clinical severity and biological complexity, research efforts are focused on understanding and targeting intratumoral heterogeneity, adaptive resistance, drug delivery barriers, and the immunosuppressi...
Sneha R. Gupta, K. Schreck· Current Opinion in Neurology· 0 citations
Radiation therapy (RT) is a crucial component of cancer management, with most patients receiving RT at some point, often in combination with surgery or systemic treatments. Cell sparing at ultrahigh dose rates was found in in vitro cell survival fraction experiments dating back to the 1960s. In the 1970s, studies revea...
A. Petoukhova, S. Penninckx, J. Schuemann et al.· Physics in Medicine and Biol...· 0 citations
Glioblastoma (GBM) remains the most aggressive and lethal primary brain tumour, with a 5-year survival rate of only ∼13% and a recurrence rate approaching 90% within two years of diagnosis. Current treatment options include surgery followed by radiotherapy and chemotherapy, but these are limited by radioresistanc...
Riddhi Sharma, William Timbury, Sean M. Gettings et al.· Neuro-Oncology· 0 citations
Tumour-neuron interactions and malignant synapse formation drive glioblastoma progression, recurrence and neurological dysfunction, but systemic inhibition of synaptic signalling causes unacceptable neurotoxicity. Here we defined the spatial and molecular determinants of malignant synapses by analysing intact human gli...